E
-101 solution is a novel antimicrobial agent with broad-spectrum activity against both Gram-negative and Gram-positive pathogens, including drug-resistant strains. E-101 solution is an enzyme-based topical formulation composed of glucose oxidase (GO) and porcine myeloperoxidase (pMPO) in an aqueous vehicle. Topical application of E-101 solution with glucose activates in situ GO production of hydrogen peroxide (H 2 O 2 ) that drives pMPO-dependent oxidation of chloride to hypochlorous acid (HOCl). The reaction of H 2 O 2 with HOCl yields singlet molecular oxygen ( E-101 solution represents the first-in-class topical myeloperoxidase-based microbicidal formulation applied directly to surgical wounds to prevent surgical-site infections (SSI). It is currently being tested in a pivotal phase 3 clinical trial (i.e., the Triple-IN Study) for the prevention of SSI after colorectal surgery. Infections caused by antimicrobial-resistant pathogens have become common and are increasingly difficult to treat (7) . As part of the clinical development of E-101 solution, it is important to monitor any changes in activity that may indicate the emergence of resistance. This study reports the in vitro susceptibility results of E-101 solution against target SSI pathogens isolated from relevant clinical specimens from patients seeking medical care in the United States over a 5-year period (2008 to 2012). In addition, we evaluated the activity of E-101 solution against highly resistant ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens and other current problem pathogens with emerging resistance (8, 9) .
A total of 760 nonduplicate, nonconsecutive clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, enterococci, Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae), and Pseudomonas aeruginosa collected from 75 sites across the 9 U.S. census regions were evaluated (Table 1 ). Among the isolates tested were those with multidrug-resistant (MDR) phenotypes. A total of 103 nonduplicate clinical isolates of ESKAPE pathogens were preselected based on resistance phenotype and genetic characterization from both the Eurofins Medinet and NARSA repositories ( 10 Acinetobacter baumannii and 10 P. aeruginosa isolates. ESBLs were phenotypically defined on prior testing as a Ͼ2-fold reduction in ceftazidime/cefotaxime MIC when combined with clavulanic acid (10). KPC-2 and KPC-3 carbapenemases were confirmed by real-time PCR (11) . Derepressed AmpC cephalosporinase was phenotypically defined on prior testing as resistant to cefoxitin, ceftazidime, and cefotaxime, not inhibited by clavulanic acid, and susceptible to carbapenems (12) . MDR bacteria were classified based on prior testing and on recommended guidelines (13) . MDR bacteria were defined as nonsusceptible to Ն1 antimicrobial agents in Ն3 antimicrobial classes.
Antimicrobial susceptibility testing was performed using a modified broth microdilution method based on CLSI M7 guidelines as previously described (14, 15) . Modifications to CLSI M7 were made to accommodate the rapid in vitro activity of E-101 solution. In the modified method, the first E-101 enzyme solution containing pMPO was diluted in double-strength cationadjusted Mueller-Hinton broth (CAMHB), resulting in doubling dilutions throughout the microdilution panel. Next, a standardized bacterial suspension, prepared in double-strength glucose substrate solution, was added to each well and mixed with enzyme dilutions. Each antimicrobial agent and enzyme solution was diluted in CAMHB and dispensed in microdilution panels. Isolates were prepared by suspending several colonies from an overnight culture on Trypticase soy agar with 5% sheep blood in sterile saline, and the density was adjusted to a turbidity equivalent to that of a 0.5 McFarland standard (ϳ10 8 CFU/ml). Standardized bacterial suspensions were further diluted in double-strength glucose substrate solution and mixed with serial drug dilutions to achieve a final concentration of 5 ϫ 10 5 CFU/ml. E-101 solution begins to generate reactive oxygen species immediately postinoculation, The microdilution panels were incubated in ambient air at 35°C for 18 to 24 h. MICs were determined by observing the lowest concentration of antimicrobial agent that inhibited growth of the organisms and was expressed as g pMPO/ml in E-101 solution.
Quality control ranges determined for E-101 solution for S. aureus ATCC 29213 and E. coli ATCC 25922 were 0.01 to 0.03 g pMPO/ml and 0.15 to 0.5 g pMPO/ml, respectively (14) . Isolates were concurrently tested against relevant comparators in accordance with CLSI M7 (13) . Quality control organisms included S. aureus ATCC 29213, E. faecalis ATCC 29212, E. coli ATCC 25922, and P. aeruginosa ATCC 27853. Table 1 The activity of E-101 solution against resistant ESKAPE pathogens was equivalent to that observed for E-101 solution during recent surveillance testing, where isolates with these phenotypes were infrequent or not encountered ( Table 2 ). E-101 solution maintained potent MICs (0.015 g pMPO/ml or less excluding one daptomycin-nonsusceptible isolate) overall against S. aureus isolates, including those resistant to current agents against Grampositive organisms. E-101 solution was active against prevalent HA-MRSA and CA-MRSA clones. Among the enterococci, E-101 solution maintained potency against vancomycin-resistant enterococci, with MICs in the 0.03-to 0.12-g pMPO/ml range. E-101 solution MICs were 2-fold lower against vancomycin-resistant E. faecium (0.03 to 0.06 g pMPO/ml) than vancomycinresistant E. faecalis (0.06 to 0.12 g pMPO/ml). Against various species and types of ␤-lactamase-producing Enterobacteriaceae, E-101 solution maintained potent MICs, including the recently emerged KPC-producing K. pneumoniae. Against A. baumannii, including all evaluated MDR A. baumannii isolates, E-101solution had MICs of 0.03 g pMPO/ml. E-101 solution was also highly active against MDR P. aeruginosa, with an MIC 50 of 0.03 g pMPO/ml and an MIC 90 of 0.06 g pMPO/ml.
Prevention of SSIs remains an important medical need in highrisk surgical patient populations, such as colorectal surgery patients, transplant patients, and patients receiving implant devices. Improvement in infection control practices and topical antiseptics that are tissue safe and broadly microbicidal for any potential pathogen for wound management are needed. Topical antiseptics currently on the market are associated with local tissue injury and impairment of wound healing when applied directly to clean or infected wounds. E-101 solution is intended for direct application to wounds and wound margins without associated tissue injury. Previous studies using the partial full-thickness pig wound model have shown that topical application of E-101 solution to surgical wounds does not impair subsequent wound healing (16) . Furthermore, E-101 solution has demonstrated in vivo efficacy in wholeanimal models of surgical infection prevention (17, 18) .
Across in vitro studies to date, E-101 solution has demonstrated greater overall in vitro activity than gentamicin and mupirocin against both Gram-negative and Gram-positive pathogens (14) . Data from this surveillance study confirm earlier studies and demonstrate that E-101 solution had high in vitro potency and a broad spectrum of activity against many circulating isolates in the United States during 2008 and 2012. In addition, E-101 solution was potent in vitro against ESKAPE pathogens, which constitute clinically important pathogens with problematic mechanisms of resistance to commonly utilized agents. The emergence and spread of resistance combined with the increasing prevalence of multidrug resistance among ESKAPE pathogens have left relatively few effective therapeutic options for the treatment of drugresistant infections. This attribute highlights the important utility of E-101 solution as a prophylactic agent for the prevention of SSIs, where resistant organisms are likely to be encountered, as well as other superficial infections caused by resistant organisms.
In summary, the MIC results of this longitudinal 5-year surveillance study indicate that E-101 continues to maintain a high level of activity against all target organism groups. No significant longitudinal changes in MICs further support the efficacy of E-101 solution, especially for preventing SSIs with organisms likely to be encountered clinically at present, including those with problematic resistance to other currently utilized agents. Continued monitoring of E-101 solution activity is warranted during clinical testing so that any changes in the level of activity can be detected in a timely matter.
